The emerging field of oncolytic virus-based cancer immunotherapy.
Trends Cancer
; 9(2): 122-139, 2023 02.
Article
en En
| MEDLINE
| ID: mdl-36402738
ABSTRACT
Oncolytic viruses (OVs) provide novel and promising therapeutic options for patients with cancers resistant to traditional therapies. Natural or genetically modified OVs are multifaceted tumor killers. They directly lyse tumor cells while sparing normal cells, and indirectly potentiate antitumor immunity by releasing antigens and activating inflammatory responses in the tumor microenvironment. However, some limitations, such as limited penetration of OVs into tumors, short persistence, and the host antiviral immune response, are impeding the broad translation of oncolytic virotherapy into the clinic. If these challenges can be overcome, combination therapies, such as OVs plus immune checkpoint blockade (ICB), chimeric antigen receptor (CAR) T cells, or CAR natural killer (NK) cells, may provide powerful therapeutic platforms in the clinic.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Virus Oncolíticos
/
Viroterapia Oncolítica
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Trends Cancer
Año:
2023
Tipo del documento:
Article